TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Imugene ( (AU:IMU) ) has shared an update.
Imugene Limited has successfully completed its Share Purchase Plan, raising $2.42 million through the issuance of over 7.3 million shares at $0.33 each. This follows a prior institutional placement that raised $22.5 million. The funds will support Imugene’s ongoing efforts in developing novel cancer therapies, reinforcing its position in the immuno-oncology sector and demonstrating strong investor confidence in its strategic direction.
The most recent analyst rating on (AU:IMU) stock is a Sell with a A$0.50 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.
More about Imugene
Imugene is a clinical stage immuno-oncology company focused on developing innovative immunotherapies to activate the immune system in cancer patients. Their platform technologies aim to harness the body’s immune response to target and eliminate tumors, with a pipeline that includes cell therapy CAR T drugs and oncolytic virotherapy. Imugene collaborates with international cancer experts to transform cancer treatment and improve patient outcomes.
Average Trading Volume: 1,709,987
Technical Sentiment Signal: Sell
Current Market Cap: A$75.01M
Learn more about IMU stock on TipRanks’ Stock Analysis page.